南新制药(688189.SH)业绩快报：2025年净亏损1.37亿元

Core Insights - The company reported a significant decline in revenue and net profit for the year 2025, with total revenue of 142 million yuan, a decrease of 46.09% compared to the previous year [1] - The net profit attributable to the parent company was a loss of 137.25 million yuan, indicating a challenging financial period [1] - Factors contributing to the decline include intensified market competition due to domestic pharmaceutical procurement policies and the introduction of similar competing products, as well as a lower incidence of flu in the domestic market during the first three quarters of 2025 [1] Financial Performance - The company's operating revenue for 2025 was 142 million yuan, down 46.09% year-on-year [1] - The net profit attributable to the parent company was a loss of 137.25 million yuan [1] - Despite the losses, the company managed to significantly reduce the loss margin compared to the previous year [1] Market Conditions - The domestic pharmaceutical industry is experiencing increased competition due to the deepening implementation of centralized procurement policies and the launch of similar competing products [1] - The lower incidence of flu in the domestic market during the first three quarters of 2025 has also negatively impacted revenue and gross margin [1] Strategic Initiatives - The company has maintained a high level of research and development investment to sustain its core competitiveness, despite the financial losses [1] - Asset impairment losses and credit impairment losses were recognized based on prudence principles in accordance with accounting standards [1]